Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.

@article{Thomas2017PrognosticEO,
  title={Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.},
  author={Derek Thomas and Hristos Z. Kaimakliotis and Kevin R. Rice and Jos{\'e} Aires Pereira and Paul Johnston and Marietta L Moore and Angela D Reed and Dylan M Cregar and C. P. Franklin and Rhoda L Loman and Michael O Koch and Richard Bihrle and Richard S. Foster and Timothy A Masterson and Thomas Allen Gardner and Chandru Sundaram and Charles R. Powell and Stephen D. W. Beck and David J. Grignon and Liang Cheng and Costantine Albany and Noah M. Hahn},
  journal={Clinical genitourinary cancer},
  year={2017},
  volume={15 4},
  pages={
          479-486
        }
}
BACKGROUND Carcinoma in situ (CIS) is a poor prognostic finding in urothelial carcinoma. However, its significance in muscle-invasive urothelial carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) is uncertain. We assessed the effect of CIS found in pretreatment transurethral resection of bladder tumor (TURBT) biopsies on the pathologic and clinical outcomes. MATERIALS AND METHODS Subjects with MIUC treated with NAC before cystectomy were identified. The pathologic complete response… CONTINUE READING